[Follow-up of osteoporosis treatment].
There is no linear relation between changes in bone mineral density (BMD) and reduction in fracture risk with antiresorptive agents. Interpretation of BMD changes at the individual level requires calculating the smallest significant change at each measurement center. BMD measurement is essential before administration of antiresorptive or anabolic agents for prevention or treatment of postmenopausal osteoporosis. Biochemical markers of bone turnover can be monitored after 6 months of treatment. Their interpretation requires careful assessment of their intraindividual variability.
Lespessailles
Eric
E
Service de rhumatologie, CHR, Orléans (45). eric.lespessailles@chr-orleans.fr
D000368:Aged; D015415:Biomarkers; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016723:Bone Remodeling; D002986:Clinical Trials as Topic; D016001:Confidence Intervals; D003720:Densitometry; D005260:Female; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D010010:Osteoclasts; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D011859:Radiography; D012307:Risk Factors; D016103:Spinal Fractures / Q000000981:diagnostic imaging / Q000517:prevention & control; D013997:Time Factors
D015415:Biomarkers; D050071:Bone Density Conservation Agents